NASDAQ:ARIA Ariad Pharmaceuticals (ARIA) Stock Price, News & Analysis → Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks (From The Oxford Club) (Ad) Free ARIA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.99▼$23.9950-Day Range N/A52-Week Range$4.67▼$23.99VolumeN/AAverage Volume15.70 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Ariad Pharmaceuticals alerts: Email Address Ad Eagle PublishingTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its kind in the U.S. It’s in a prime position to profit.For the full story, click here About Ariad Pharmaceuticals Stock (NASDAQ:ARIA)ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).Read More Ad Eagle PublishingTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its kind in the U.S. It’s in a prime position to profit.For the full story, click here ARIA Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comIDRx Appoints David P. Kerstein, M.D., as Chief Medical OfficerMarch 12, 2024 | finance.yahoo.comIDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBOMarch 8, 2024 | msn.comWhat Is Donanemab? Eli Lilly’s Alzheimer’s Drug Gets Delayed Decision From FDAMarch 4, 2024 | bizjournals.comTakeda extends lease in Kendall Square through 2040February 13, 2024 | finance.yahoo.comIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesJanuary 3, 2024 | msn.comVeteran biotech entrepreneur Harvey Berger to lead startup Kojin TherapeuticsJanuary 3, 2024 | bizjournals.comHarvey Berger leaves biotech 'sidelines' for new CEO gigOctober 26, 2023 | msn.comBiogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's TreatmentOctober 12, 2023 | benzinga.comLeukemia Therapeutics Treatment Market Set to Achieve US$ 30,318.5 Million by 2033 at 7.1% CAGR | Future Market Insights Inc.September 6, 2023 | fortune.comKickstarter’s new finance chief is ultra-extroverted—and she credits that trait to her success as a ‘people-centric CFO’August 24, 2023 | finance.yahoo.comChronic Lymphocytic Leukemia Treatment Global Market Report 2023August 20, 2023 | thestreet.comAriad Stock Falls On Unusually High Volume (ARIA)July 19, 2023 | msn.comSecond Alzheimer’s drug to slow disease’s progression may be approved in the US this yearJuly 17, 2023 | cbsnews.comSecond Alzheimer's drug to slow disease's progression may be approved in the US this yearJune 28, 2023 | finance.yahoo.comSarissa Capital Urges Alkermes Shareholders to Vote "FOR" Sarah Schlesinger and "WITHHOLD" Incumbent Director Richard GaynorJune 26, 2023 | washingtonpost.comActivist Pro Tip: Don’t Put Your Girlfriend on the BoardMay 17, 2023 | marketwatch.comPonatinib Market Research | 2023-2030May 16, 2023 | marketwatch.comComprehensive Analysis of Cancer Treatment Drugs Market Trends and Growth 2023-2030May 14, 2023 | marketwatch.comIclusig Market Research | 2023-2030May 10, 2023 | marketwatch.comUterine Cancer Therapies and Diagnostic Market Forecast 2023-2030May 5, 2023 | marketwatch.comThe Global Targeted Drugs for NSCLC Market Size is expanding rapidly, with a CAGR of 12.2% from 2023 to 2030May 5, 2023 | marketwatch.comChronic Myeloid Leukemia (CML) Treatment Market 2023 [New Report forecast 2030] Current and Future TrendsMay 3, 2023 | msn.comEli Lilly Surges After Alzheimer's Treatment Succeeds; Biogen Also RisesMay 3, 2023 | marketwatch.comAcute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Analysis and Forecast to 2031May 3, 2023 | marketwatch.comCancer Drugs Market Applications and Types with Regional Analysis 2023-2031See More Headlines Receive ARIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ariad Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/28/2016Today6/14/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:ARIA CUSIP04033A10 CIK884731 Webwww.ariad.com Phone+1-617-4940400FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key CompetitorsAmgenNASDAQ:AMGNVertex PharmaceuticalsNASDAQ:VRTXRegeneron PharmaceuticalsNASDAQ:REGNGilead SciencesNASDAQ:GILDBiogenNASDAQ:BIIBView All Competitors ARIA Stock Analysis - Frequently Asked Questions How were Ariad Pharmaceuticals' earnings last quarter? Ariad Pharmaceuticals Inc (NASDAQ:ARIA) issued its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.70. The pharmaceutical company earned $65.30 million during the quarter, compared to analysts' expectations of $60.64 million. The business's quarterly revenue was up 133.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.28) earnings per share. What other stocks do shareholders of Ariad Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ariad Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Twitter (TWTR), Exelixis (EXEL), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Achillion Pharmaceuticals (ACHN), Array Technologies (ARRY), Alphabet (GOOG), Netflix (NFLX) and Ford Motor (F). This page (NASDAQ:ARIA) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ariad Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ariad Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.